Production (Stage)
Regencell Bioscience Holdings Limited
RGC
$14.17
-$0.5132-3.50%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 977.60K | 977.60K | 913.60K | 913.60K | 1.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.21M | 1.21M | 1.16M | 1.16M | 1.42M |
| Operating Income | -1.21M | -1.21M | -1.16M | -1.16M | -1.42M |
| Income Before Tax | -1.09M | -1.09M | -1.09M | -1.09M | -1.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.09M | -1.09M | -1.09M | -1.09M | -1.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -28.90K | -28.90K | 59.60K | 59.60K | 51.70K |
| Net Income | -1.12M | -1.12M | -1.03M | -1.03M | -1.32M |
| EBIT | -1.21M | -1.21M | -1.16M | -1.16M | -1.42M |
| EBITDA | -1.14M | -1.14M | -1.08M | -1.08M | -1.35M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | -- | -- | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | -- | -- | 0.00 |
| Average Basic Shares Outstanding | 494.49M | 494.49M | 494.49M | 494.49M | 494.49M |
| Average Diluted Shares Outstanding | 494.49M | 494.49M | 494.49M | 494.49M | 494.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |